HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Health And Wellness Executive Decisions: Herbalife, Bausch + Lomb, Cascadia Capital

Executive Summary

Herbalife distributor leaves board to be strategy chief; Bausch + Lomb increases executive posts; and Cascadia Capital director’s focus includes sports nutrition.

You may also be interested in...



US Q3 Consumer Health Earnings Preview: Phenylephrine Question Punctuates Quarter

Consumer health products sector’s earnings reports for July-September period are its first since FDA advisory committee unanimously voted that results of research agency presented show oral phenylephrine at OTC monograph doses is ineffective to treat nasal congestion.

With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb

“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.

Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions

After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel